Charles River [CRL] vs Guardant Health [GH] Detailed Stock Comparison
Charles River
NYSE
Loading...
Guardant Health
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Charles River wins in 10 metrics, Guardant Health wins in 8 metrics, with 0 ties. Charles River appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Charles River | Guardant Health | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 681.33 | -17.45 | Guardant Health |
| Price-to-Book Ratio | 2.16 | -25.24 | Guardant Health |
| Debt-to-Equity Ratio | 82.04 | -4.37 | Guardant Health |
| PEG Ratio | -17.28 | 3.66 | Charles River |
| EV/EBITDA | 10.35 | -20.38 | Guardant Health |
| Profit Margin (TTM) | -1.66% | -49.93% | Charles River |
| Operating Margin (TTM) | 16.67% | -45.75% | Charles River |
| EBITDA Margin (TTM) | 16.67% | N/A | N/A |
| Return on Equity | -1.81% | 312.48% | Guardant Health |
| Return on Assets (TTM) | 4.31% | -19.57% | Charles River |
| Free Cash Flow (TTM) | $501.61M | $-274.94M | Charles River |
| 1-Year Return | -8.03% | 177.35% | Guardant Health |
| Price-to-Sales Ratio (TTM) | 1.81 | 9.33 | Charles River |
| Enterprise Value | $9.89B | $8.54B | Charles River |
| EV/Revenue Ratio | 2.45 | 10.31 | Charles River |
| Gross Profit Margin (TTM) | 34.59% | 65.01% | Guardant Health |
| Revenue per Share (TTM) | $80 | $7 | Charles River |
| Earnings per Share (Diluted) | $-1.29 | $-3.46 | Charles River |
| Beta (Stock Volatility) | 1.47 | 1.46 | Guardant Health |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Charles River vs Guardant Health Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Charles River | 2.86% | 20.46% | 8.75% | 11.35% | 17.47% | -3.99% |
| Guardant Health | -1.90% | 2.13% | -7.59% | 22.48% | 41.32% | 93.45% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Charles River | -8.03% | -14.57% | -27.68% | 171.42% | 438.76% | 310.82% |
| Guardant Health | 177.35% | 10.24% | -43.19% | 110.48% | 110.48% | 110.48% |
News Based Sentiment: Charles River vs Guardant Health
Charles River
News based Sentiment: POSITIVE
The month of October saw a continuation of positive momentum for Charles River Laboratories, driven by multiple analyst upgrades and increased price targets following a strong Q2 earnings report. While some insider selling and mixed institutional activity exist, the overall narrative is one of growing optimism and potential for further growth.
Guardant Health
News based Sentiment: POSITIVE
Guardant Health delivered a strong Q2 performance with revenue exceeding expectations and raised full-year guidance. A significant legal victory and key partnerships further bolster the company's position, though continued cash burn remains a concern. These developments suggest a positive trajectory for the company, making October a significant month for investors.
Performance & Financial Health Analysis: Charles River vs Guardant Health
| Metric | CRL | GH |
|---|---|---|
| Market Information | ||
| Market Cap | $7.23B | $7.73B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 990,510 | 2,782,030 |
| 90 Day Avg. Volume | 826,430 | 2,486,587 |
| Last Close | $175.36 | $61.46 |
| 52 Week Range | $91.86 - $230.02 | $20.14 - $68.00 |
| % from 52W High | -23.76% | -9.62% |
| All-Time High | $460.21 (Sep 20, 2021) | $181.07 (Feb 08, 2021) |
| % from All-Time High | -61.90% | -66.06% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.01% | 0.31% |
| Quarterly Earnings Growth | -0.44% | 0.31% |
| Financial Health | ||
| Profit Margin (TTM) | -0.02% | -0.50% |
| Operating Margin (TTM) | 0.17% | -0.46% |
| Return on Equity (TTM) | -0.02% | 3.12% |
| Debt to Equity (MRQ) | 82.04 | -4.37 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $68.14 | $-2.45 |
| Cash per Share (MRQ) | $3.72 | $4.19 |
| Operating Cash Flow (TTM) | $787.45M | $-238,546,000 |
| Levered Free Cash Flow (TTM) | $706.38M | $-131,174,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | $0.00 | N/A |
Valuation & Enterprise Metrics Analysis: Charles River vs Guardant Health
| Metric | CRL | GH |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 681.33 | -17.45 |
| Forward P/E | 14.30 | -22.87 |
| PEG Ratio | -17.28 | 3.66 |
| Price to Sales (TTM) | 1.81 | 9.33 |
| Price to Book (MRQ) | 2.16 | -25.24 |
| Market Capitalization | ||
| Market Capitalization | $7.23B | $7.73B |
| Enterprise Value | $9.89B | $8.54B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.45 | 10.31 |
| Enterprise to EBITDA | 10.35 | -20.38 |
| Risk & Other Metrics | ||
| Beta | 1.47 | 1.46 |
| Book Value per Share (MRQ) | $68.14 | $-2.45 |
Financial Statements Comparison: Charles River vs Guardant Health
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CRL | GH |
|---|---|---|
| Revenue/Sales | $984.17M | $203.47M |
| Cost of Goods Sold | $666.44M | $74.72M |
| Gross Profit | $317.73M | $128.75M |
| Research & Development | N/A | $88.52M |
| Operating Income (EBIT) | $74.67M | $-111.04M |
| EBITDA | $184.23M | $-83.84M |
| Pre-Tax Income | $35.98M | $-94.87M |
| Income Tax | $10.10M | $290,000 |
| Net Income (Profit) | $25.88M | $-95.16M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CRL | GH |
|---|---|---|
| Cash & Equivalents | $229.36M | $698.57M |
| Total Current Assets | $1.51B | $927.03M |
| Total Current Liabilities | $1.05B | $225.75M |
| Long-Term Debt | $2.99B | $1.28B |
| Total Shareholders Equity | $3.24B | $-250.79M |
| Retained Earnings | $1.84B | $-2.67B |
| Property, Plant & Equipment | $402.91M | $140.50M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CRL | GH |
|---|---|---|
| Operating Cash Flow | $130.09M | $-49.41M |
| Capital Expenditures | N/A | $-4.46M |
| Free Cash Flow | $112.37M | $-67.15M |
| Debt Repayment | $-149.39M | N/A |
| Common Stock Repurchase | $-353.13M | $-45.01M |
Short Interest & Institutional Ownership Analysis
| Metric | CRL | GH |
|---|---|---|
| Shares Short | 2.56M | 8.74M |
| Short Ratio | 3.38 | 3.67 |
| Short % of Float | 0.06% | 0.07% |
| Average Daily Volume (10 Day) | 990,510 | 2,782,030 |
| Average Daily Volume (90 Day) | 826,430 | 2,486,587 |
| Shares Outstanding | 51.14M | 123.99M |
| Float Shares | 48.62M | 119.85M |
| % Held by Insiders | 0.01% | 0.04% |
| % Held by Institutions | 1.06% | 0.99% |
Dividend Analysis & Yield Comparison: Charles River vs Guardant Health
| Metric | CRL | GH |
|---|---|---|
| Last 12-Month Dividend | $0.00 | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | $0.00 | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | $0.00 | N/A |
| Ex-Dividend Date | N/A | N/A |